Synergistic CAR-T Cell Therapy System

Publication ID: 24-11857572_0003_PTD
Published: October 28, 2025
Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic CAR-T Cell Therapy System,” Published Technical Disclosure No. 24-11857572_0003_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857572_0003_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,572.

Summary of the Inventive Concept

A novel system integrating CAR-T cell therapy with AI, IoT, blockchain, and nanomaterials to enhance T cell potency, optimize treatment protocols, and ensure secure patient data management.

Background and Problem Solved

The original patent discloses a method for preparing CAR-T cells with TCM as the main active component. However, the existing method lacks real-time monitoring, personalized treatment, and secure data management. The new inventive concept addresses these limitations by incorporating cutting-edge technologies to create a more powerful and efficient CAR-T cell therapy system.

Detailed Description of the Inventive Concept

The Synergistic CAR-T Cell Therapy System consists of a blockchain-based decentralized storage unit for storing T cell subset data, an AI-powered processing module for analyzing and optimizing T cell differentiation protocols, a wearable IoT device for real-time monitoring of T cell activity, and a cloud-based data analytics platform for tracking patient response and optimizing treatment protocols. Additionally, the system integrates a genetic testing module for identifying patient-specific genetic markers, a nanomaterial-based delivery system for targeted delivery of T cell stimulants, and an AI-powered optimization module for identifying optimal stimulant dosages and delivery protocols.

Novelty and Inventive Step

The new claims introduce the synergistic integration of AI, IoT, blockchain, and nanomaterials with CAR-T cell therapy, providing a novel and non-obvious solution for enhancing T cell potency, optimizing treatment protocols, and ensuring secure patient data management.

Alternative Embodiments and Variations

Alternative embodiments may include the use of different AI algorithms, IoT devices, or blockchain platforms. Variations may also involve the integration of additional technologies, such as CRISPR gene editing or synthetic biology, to further enhance the CAR-T cell therapy system.

Potential Commercial Applications and Market

The Synergistic CAR-T Cell Therapy System has significant commercial potential in the cancer treatment market, with potential applications in personalized medicine, precision oncology, and regenerative medicine.

Field of Art

Immunotherapy, cellular engineering, specifically CAR-T cell development and optimization with focus on central memory T cell (Tcm) subset manipulation

Person of Ordinary Skill (PHOSITA) Profile

A biomedical engineer or immunologist with advanced degree, expertise in cellular therapy, familiarity with AI/machine learning applications in biotechnology, understanding of computational biology techniques

Obviousness Rationale

A PHOSITA would recognize that integrating computational technologies with CAR-T cell development represents a natural progression in personalized medicine. The source patent's foundational work on Tcm cell manipulation provides a clear technological framework that can be extended through emerging digital technologies. The proposed variations represent predictable applications of known computational techniques to an established cellular engineering methodology.

Obvious Combinations & Variations

Source Patent Element
CAR-T cell method focusing on central memory T cell subset
PTD Variation
AI-powered processing module for analyzing T cell differentiation protocols
Obviousness Reasoning
Machine learning algorithms are well-established for optimizing biological processes, representing a known technique for enhancing existing cellular engineering methodologies
Source Patent Element
T cell subset with specific surface markers (CD45RO+/CD197+)
PTD Variation
Genetic testing module for identifying patient-specific genetic markers
Obviousness Reasoning
Personalized medicine approaches that correlate genetic markers with cellular therapies are a predictable extension of existing immunological research strategies
Source Patent Element
CAR-T cell activation method
PTD Variation
Blockchain-based decentralized storage for T cell subset data
Obviousness Reasoning
Secure data management techniques are a standard approach for handling sensitive medical research information, representing an obvious technological enhancement
Source Patent Element
Artificial antigenic epitope in CAR extracellular domain
PTD Variation
Nanomaterial-based delivery system for targeted T cell stimulant delivery
Obviousness Reasoning
Advanced drug/stimulant delivery mechanisms are a predictable technological progression in cellular engineering, utilizing finite identified solution sets
Source Patent Element
T cell subset characterization method
PTD Variation
IoT wearable device for real-time monitoring of T cell activity
Obviousness Reasoning
Real-time biological monitoring represents a standard technological approach for tracking cellular therapies, utilizing known sensor and data collection techniques
35 U.S.C. § 103 Summary: Based on US Patent 11857572's foundational teachings regarding CAR-T cell methodology, the instant publication demonstrates that the integration of computational technologies with cellular engineering represents an obvious technological progression. A person having ordinary skill in the art would find the proposed variations to be straightforward extensions of existing immunotherapeutic research methodologies, thereby rendering potential derivative claims obvious and non-patentable.

Original Patent Information

Patent NumberUS 11,857,572
TitleMethod for preparing CAR-T cell with TCM as main active component and use thereof
Assignee(s)Xuanwu Hospital Capital Medical University